Product Information

GLEEVEC 400 MG TABLET is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $328.0342 per EA under NDC 00078064913. Its NADAC has been published 46 times since Oct 30, 2024.

FDA first approved this application on Apr 18, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the imatinib mesylate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

Price Statistics

The NADAC for GLEEVEC 400 MG TABLET has been published 46 times since Oct 30, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Generic Alternatives

The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.